Breakthrough in colorectal cancer as Regeneron Pharmaceuticals reveals promising results from immunotherapy trial
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has announced encouraging early outcomes from its Phase 1/2 clinical trial, which evaluates a new immunotherapy combination of REGN7075 and Libtayo (cemiplimab) targeting advanced solid tumors. This trial is among the first to show effectiveness in patients with microsatellite stable colorectal cancer (MSS CRC), a type traditionally resistant to immunotherapies. […]